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Abstract
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) evaluates the tissue microvasculature and
may have a role in assessing and predicting therapeutic response in prostate cancer (PCa). In this review, we
review principles of DCE-MRI and present the potential quantitative information that can be obtained. We discuss
how it may be used as a biomarker for treatment with antiangiogenic and antivascular agents and potentially iden-
tify patients with PCa who may benefit from this form of therapy. Likewise, DCE-MRI may play a role in assessing
response to combined androgen deprivation therapy and radiation therapy and theoretically could be a prognostic
biomarker in evaluating second-generation hormone therapies. We also address the challenges of using DCE-MRI
in PCa clinical trials and discuss the difficulties with standardization of this methodology to allow for biomarker
validation, with particular reference to PCa.
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Introduction
Prostate cancer (PCa) is the most common cancer in men in North
America and Europe, after nonmelanoma skin cancer, with 238,590
new cases estimated for 2013, and it is the second leading cause of
cancer-related deaths in males after lung cancer [1]. As the US popula-
tion of male “baby boomers” age, there will be an increase in PCa
diagnosis and numbers of men presenting for therapy. Incidence is
estimated to exceed 450,000 cases per year by 2015. Androgen depri-
vation therapy (ADT) is often first line for those who relapse after
treatment of organ-confined disease or for advanced disease at the
time of diagnosis. However, responses are not durable, and metastatic
disease from castration-resistant prostate cancer (CRPC) is fatal. Angio-
genesis has been shown to play a central role in the progression of
CRPC [2], and microvessel density has been shown to correlate with
Gleason score and predict disease progression [2–5]. However, unlike
other solid tumors where inhibition of angiogenic pathways has been
shown to be an effective treatment strategy [6–9], the role of anti-
angiogenic therapy in the management of PCa still remains to be
defined [10]. In CRPC, the androgen receptor (AR) has been found
to be the key regulator and driver of tumor growth, spread, and survival
and the most promising therapeutic target [11]. As such, with the
introduction of novel second-generation hormone therapies such
as abiraterone and enzalutamide in the last few years, the treatment
paradigms for CRPC appear to be rapidly changing.
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)
is the fast acquisition of MR images after the rapid IV bolus injection of
gadolinium chelate contrast agent and is used to evaluate properties of
tissue microvasculature, known to have potential in clinical oncology as
a noninvasive imaging biomarker [12]. DCE images can be analyzed in
a qualitative and/or quantitative manner. Qualitative visual assessment
of enhancement is a common tool in image analysis used in everyday
clinical practice. The quantitative assessment requires postacquisition
processing and allows calculation of estimates of tissue perfusion,
microvascular wall permeability, plasma volume fraction, and the
extracellular volume fraction. Driven by demands for imaging as a
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noninvasive biomarker in assessing response to therapy, the usefulness
of this quantitative approach has been recognized and demonstrated in
evaluating treatment response in many tumors such as breast cancer
[13,14], renal cell carcinoma [15,16], and others [17]. DCE-MRI
has potential for assessing and predicting therapeutic response to anti-
angiogenic and vascular targeting agents in PCa. Likewise, DCE-MRI
may play a role in assessing response to combined ADT and radiation
therapy. Its role as a predictive or prognostic biomarker in second-
generation hormone therapies remains to be investigated. This review
highlights the rationale for using DCE-MRI in PCa clinical trials,
presents the potential quantitative information that can be obtained,
and discusses the challenges and possible pitfalls.
Rationale for Antiangiogenic Therapy in PCa
Tumor vascularization is a complex process that involves interactions
between the tumors and their surrounding stroma, in addition to
proangiogenic and antiangiogenic regulating factors. A number of
angiogenic agents have been implicated in PCa progression, such as
vascular endothelial growth factor (VEGF), fibroblast growth factor
(FGF), and hepatocyte growth factor [18–21]. The expression of
VEGF receptor 1 has been correlated with higher Gleason score [22].
In contrast to recent results with second-generation hormonal therapies
[23–26], however, phase III studies of antiangiogenic agents in CRPC
have failed to meet their primary end points [10,27,28]. Although the
role for antiangiogenic agents remains controversial, the preclinical
rationale for their use is strong. Development of predictive biomarkers
to identify the appropriate subgroup of patients that may benefit from
this form of targeted therapy is a current need, especially considering
the added toxicity reported with some antiangiogenic studies [28].
Recent Developments in Treatment of CRPC
Androgens have been shown to stimulate key angiogenic events in male
cells in vitro, sex-specific proangiogenic effects that are mediated
through the AR [29]. Recently, clinical studies have confirmed that
advanced PCa is driven by AR signaling. The androgen biosynthesis
inhibitor abiraterone acetate was the first second-line hormonal agent
to improve survival in metastatic CRPC [23,24]. It selectively inhibits
cytochrome P450 17 α-hydroxylase and cytochrome17,20-lyase,
enzymes critical for androgen synthesis. The Food and Drug Adminis-
tration (FDA) recently expanded its indication for use in the pre-
chemotherapy setting after abiraterone elicited significant delays in
disease progression and a strong trend for increased overall survival in
phase III studies [25]. The AR inhibitor enzalutamide has also demon-
strated survival benefit in phase III studies in CRPC [26]. An interna-
tional phase III trial (AFFIRM) was halted after an interim analysis
revealed that patients given the drug lived for approximately 5 months
longer than those taking placebo [26], and a subsequent trial (PRE-
VAIL) demonstrated effectiveness of enzalutamide in patients who
had not yet received chemotherapy [30]. Given that PCa is a very
heterogenous disease, an individualized approach may be required to
maximize potential benefits from novel or combination therapies.
Rationale for Using DCE-MRI in PCa
Multiparametric MRI (mpMRI) of the prostate, the current clinical
standard, refers to a set of sequences that include T 2-weighted imaging
(T2WI), diffusion-weighted imaging (DWI), and DCE-MRI. mpMRI
is known to play an important role in PCa detection and localization
and PCa staging [31,32]. It also aids in tumor detection when there is
a biochemical suspicion of residual or recurrent disease after treatment
[33–35]. Compared to conventional prostate MR techniques from 5
to 10 years ago, which relied on morphology alone for tumor staging,
localization, and characterization, standard-of-care prostate MR in
2013 provides a wealth of information regarding tumor functionality.
Each of the individual sequences provides unique and complementary
data. DWI is reflective of the random motion of water molecules at
a cellular level and is thus sensitive to cell membrane integrity, hyper-
cellularity, enlargement of the nuclei, and hyperchromatism. DWI
[and more specifically, apparent diffusion coefficient (ADC), a quanti-
tative metric derived from DWI] has been demonstrated on multiple
occasions to inversely correlate with Gleason score and serve as a bio-
marker for prostate tumor aggressiveness [36–41]. DWI as a physiolog-
ical measure also has the added benefit of not requiring injection of
gadolinium chelates.
Unique capabilities of DCE also hold much promise for better
characterizing PCa. On DCE, focal areas of PCa show early strong
enhancement when compared to surrounding normal prostate tissue
[42], as the number of vessels in tumor foci increase, and these newly
formed tumor vessels (neovascularity) have higher permeability and
more heterogeneous architecture than do normal vessels [22]. Immuno-
histochemical determination of microvessel density, which provides a
count of the number of vessels per area, is significantly higher in PCa
compared with normal prostate tissue [43,44]. A poorer prognosis has
also been found to correlate with increasing irregularity and decreasing
size of the new vessels [4,45]. These histologic observations highlight the
potential of DCE-MRI for noninvasively assessing themicrovasculariza-
tion and angiogenesis in PCa, and indeed, DCE-MRI parameters
have been demonstrated to correlate with microvessel density [46,47].
A recent study has shown that DCE-MRI quantitative parameters
have the potential to assess PCa aggressiveness (low grade from inter-
mediate and high grade) in the prostate peripheral zone [48]. DCE-
MRI can be measured repeatedly and noninvasively, and because of
the intrinsic soft-tissue contrast provided by MRI, it is an appealing
biomarker to assess properties of the microcirculation that may capture
the heterogeneity of tumor and its response to treatment. As a reflec-
tion of the value of DCE-MRI in the routine prostate clinical care, its
use is recommended to be included in the standard prostate staging
and assessment protocol [49].
Prostate DCE-MRI: Principles and Technique
DCE-MRI of the prostate is performed by rapid imaging after IV
administration of a gadolinium chelate. MR contrast agents are special-
ized compounds that alter the magnetic properties of tissues and their
neighboring protons. By observing the MR signal change caused by
the shortening of the T 1 relaxation time, the concentration of the
contrast agent at a given voxel can be measured, allowing the study
of the distribution of the contrast agent over time. Molecules of the
contrast agent can pass through the blood vessel walls and enter the
extracellular extravascular space but cannot penetrate the cellular
membrane and are gradually washed out and excreted by the kidneys.
In the prostate, the passage of the contrast agent through the gland is
typically captured by specialized fast-imaging sequences, initiated be-
fore the contrast agent is injected to enable assessment of the baseline
pre-enhancement properties of the tissue (Figure 1). The DCE-MRI
protocol is optimized to find a balance between the spatial (important
for localization of the lesion and assessment of disease extent) and
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temporal (important to accurately capture the peak concentration of the
contrast uptake curve) resolutions of the image. Commonly used pro-
tocols used in clinic often allow for 5- to 10-second resolution in the
prostate at 3 Tesla (3T) [32]. The acquisition should also be sufficiently
long to capture the entire circulation of contrast agent through to
venous washout (about 5 minutes) [49].
MR signal enhancement identified on DCE-MRI can be assessed in
two ways, namely, semiquantitative analysis of signal intensity changes
over time or by quantifying the amount of contrast agent concen-
tration change using pharmacokinetic (PK) modeling techniques.
Semiquantitative parameters include curve shape, maximum signal
intensity, and washout gradient. The initial area under the signal
intensity curve or contrast medium concentration (IAUGC) curve
has also been studied. Quantitative techniques require PK models that
are applied to changes in tissue contrast agent concentrations to esti-
mate contrast agent concentration in vivo. Volume transfer constant
of the contrast agent (K trans) and the rate constant (kep) are commonly
used parameters derived from quantitative techniques. In-depth dis-
cussion of PK modeling techniques is outside the scope of this paper
but can be found in many detailed reviews [50–52].
Prostate mpMRI as a Biomarker in Evaluating
Response to PCa Therapy
The broader oncology and cancer imaging community in the United
States is attempting to address the need for, and standardization and
requirements of, qualified biomarkers through collaborative efforts
between the FDA, the National Cancer Institute (NCI), and other
regulatory bodies, with the formulation of consortia such as the
Oncology Biomarkers Qualification Initiative and the American Asso-
ciation for Cancer Research (AACR)-FDA-NCI Cancer Biomarkers
Collaborative [53]. The NCI has also formed the Quantitative Imaging
Network specifically to promote research and development of quan-
titative imaging methods for the measurement of tumor response to
therapies in clinical trial settings.
In the prostate, a role for mpMRI in evaluating response to specific
PCa therapies, such as antiangiogenic therapies, and external-beam
radiation therapy and ADT are current areas of investigation. A role
for mpMRI in evaluating response to second-line hormonal therapies
remains to be determined.
Systemic Therapy
A recent review by O’Connor et al. [54] reported nearly 100 clinical
studies of antivascular agents that have incorporated DCE-MRI and
have yielded substantial data. They, however, point out that, although
DCE-MRI can detect and monitor changes in vascular function and
structure, such a change is necessary but not sufficient for proof of
concept for antivascular drugs, as a significant change in DCE-MRI
parameters is not sufficient evidence of clinically significant efficacy of
antivascular therapy. However, the amount of change in parameters can
help determine the biologically active dose (especially if there is a linear
dose-dependent correlation between therapy and DCE-MRI parameter),
optimal treatment schedule, and therapeutic window for the drug.
There has been significant evaluation of a role for DCE-MRI in
assessing response to antivascular therapy in other tumors such as
breast, lung [55], renal [15], and colon cancers [17]. In the prostate,
many preclinical studies have validated the use of DCE-MRI for
Figure 1. Data acquisition and analysis workflow. (A) High temporal resolution sequential images (approximately 50 consecutive acqui-
sitions) are obtained through the prostate, with contrast material automatically infused following five precontrast baseline acquisitions,
resulting in DCE image acquisition lasting about 5 minutes. (B) ROI for tumor (blue arrow) and AIF feeding vessel (red arrow) are defined
on subtraction DCE images. (C) Using precontrast T 1 map of native prostate tissue, signal intensity values for each voxel within the ROI
are converted into contrast agent concentration (green curve for tumor). (D) On the basis of the contrast uptake curve in the tumor
region and the concentration of the contrast agent in the feeding vessel, empirical PK parameters or derived PK parameters that require
mathematical fitting of the PK model to the concentration curves are obtained.
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monitoring the effect of antiangiogenic agents on PCa. For example, in
an experimental study evaluating the effect of sorafenib on experimental
PCa, significant correlations were found between tumor perfusion in-
dices and immunohistochemical tumor cell apoptosis and tumor vascu-
larity [56]. Sampath et al. have found that, in a prostate xenograft
model, DCE-MRI functions well as a pharmacodynamic assay to quan-
titatively measure the activity of phosphatidylinositol 3-kinase and dual
phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibi-
tors [57].
A recent clinical study in men with CRPC demonstrated the use of
DCE-MRI in predicting clinical outcomes associated with the anti-
angiogenic agent cediranib [58]. They found that baseline K trans was
significantly associated with progression-free survival, thus indicating
that DCE-MRI variables may prove effective as pharmacodynamic
predictive biomarkers of clinical outcome for cediranib. This is simi-
lar to results previously shown for sorafenib in metastatic renal cell
carcinoma [15] and non–small cell lung cancer [55].
Considering that androgens have been shown to stimulate key
angiogenic events in male cells in vitro, mediated through the AR
[29], a role for DCE-MRI in assessing response to the newer second-
generation hormonal therapies is a strong possibility. On an individual
basis, quantitative changes in mpMRI, including DCE-MRI, can be
seen in patients with CRPC treated with enzalutamide (Figure 2).
However, a role for DCE-MRI as a predictive or prognostic biomarker
for CRPC remains to be determined.
External-Beam Radiation Therapy and ADT
In preclinical studies, androgen ablation has been shown to sup-
press glandular epithelial production of VEGF and induce apoptosis
of endothelial cells [59,60]. There have been promising results from
studies evaluating a role for mpMRI to assess response to ADT
[61,62] and radiotherapy [63,64]. A DCE-MRI study found that
ADT induces profound vascular collapse within 1 month of starting
treatment [62], with significant decreases in tumor blood volume and
blood flow, which decreased by 83% and 79%, respectively, and
74% of patients showing significant changes. After ADT, prostate
gland shrinkage and fibrosis make tumor difficult to detect on routine
T2WIs, as this sequence depends heavily on tissue proton content
for contrast. A feasibility study [61] evaluated the use of mpMRI in
monitoring response to ADT and suggested that DCE as a marker of
Figure 2. Top two rows: Changes in mpMRI (T2WI, ADC maps, and the PK parameter K
trans) observed pretreatment (top row) and 180 days
posttreatment (bottom row) with enzalutamide. K trans values in the tumor area decrease from 0.82 (pretreatment) to 0.35 (posttreatment).
Graphs: Treatment-induced change is also reflected in the shapes of the contrast uptake curves. Pretreatment there is a faster uptake and
washout of contrast in the tumor, compared to normal peripheral zone. Although the degree of uptake remains higher in the tumor tissue
posttreatment, its overall shape begins to resemble that of normal peripheral zone. (Tumor in prostate peripheral zone, red slope; normal
prostate peripheral zone, green slope.)
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angiogenesis may help demonstrate ADT resistance, as ADT reduces
prostatic blood flow and oxygenation.
As changes in serum prostate specific antigen (PSA) concentrations
are not necessarily an accurate surrogate for tissue response post-ADT
[65]—PSA reduction post-ADT may be secondary to androgen sup-
pression rather than tumor cell death—it is possible that DCE may
act as a stronger surrogate for angiogenesis, rather than PSA.
A Potential Role for Prostate DCE-MRI in PCa
Drug Development
Trials of antivascular agents using DCE-MRI as an end point were
first reported in 2002 [66,67], and more recent developments have
advanced the accuracy of information that can be obtained from
DCE-MRI for early-stage clinical trials, as reported by the Imaging
Committee of the Experimental Cancer Medicine Centers [68]. In
almost all DCE-MRI studies of phase I antivascular agents to date,
DCE-MRI parameters are secondary end points, providing informa-
tion on proof of concept or on the relationship between DCE-MRI
parameters and drug PK parameters [54].
Specific to PCa, the Prostate Cancer Clinical Trials Working
Group (PCWG2) [69] has recognized that cytotoxic agents typically
result in regression of target lesions and a decrease in PSA, whereas
noncytotoxic agents that slow tumor growth or prevent angiogenesis
may not do so. Clinically meaningful responses in patients on targeted
therapy may therefore be underestimated given that these agents often
cause decreased tumor vascularity and necrosis without appreciable
reductions in tumor size. PCWG2 has suggested that response assess-
ment in phase II trials should focus on time-to-event time points.
Assessment in response to antiangiogenic therapy in PCa is chal-
lenging, as progression-free survival is difficult to define on bone scan
for distant metastases or using Response Evaluation Criteria in Solid
Tumors. Response Evaluation Criteria in Solid Tumors was primarily
designed for use with cytotoxic agents, and it has limitations when
applied to targeted therapy, which may provide clinical benefit for
patients without causing marked tumor shrinkage. As an early vali-
dated surrogate end point could help with timing of regulatory ap-
proval, many radiotracers with positron emission tomography [70]
and number of circulating tumor cells [71] are being investigated.
The PCWG3 is currently being drafted and will include recommen-
dation for imaging biomarker development in PCa trials. Identifying
a role for DCE-MRI as a predictive biomarker may allow further
insight into induced changes in microvascular structure and function
in PCa by the drug under investigation.
A Role for DCE-MRI in Helping Define the Biologically
Effective Dose
A key rationale for using DCE-MRI in early-phase trials has been
to define the biologically active dose of drugs in phase I trials and also
to inform drug scheduling and assist in dose selection for phase II
studies [72]. As reviewed by O’Connor et al. [54], reductions in
K trans and IAUGC have shown a linear dose-dependent relationship
with cediranib, sorafenib, and vatalanib in other tumors, and maximum
drug concentration in the plasma has also correlated with changes in
K trans and IAUGC following treatment. Parameter relationship to drug
exposure studies remains to be investigated in the prostate.
Selection of DCE-MRI Biomarker Parameter in PCa
Drug Development
In general, K trans and IAUGC have been used as the preferred
DCE-MRI end points in clinical trials [51,73]. K trans was chosen
as the primary end point because it reflects contrast agent delivery
(perfusion) and transport across the vascular endothelium (perme-
ability). IAUGC was chosen as an alternative semiquantitative end
point because it does not require model fitting and is therefore rela-
tively robust and comparable across sites. It is calculated from the
area under the contrast agent concentration curve up to a specified
cutoff time (usually 60 seconds). However, IAUGC does not have
a simple relation to tissue perfusion and permeability. As VEGF is
considered to reduce vascular permeability [74], it therefore should
reduce tumor K trans and would be a sensible choice if an anti-VEGF
compound is being investigated. If, however, treatment effect is
being achieved through blockade of FGF, alternate functional bio-
markers other than K trans and IAUGC should also be looked at, as
the imaging-related effects achieved through blocking FGF are not
yet understood. Likewise, as vascular targeting agents cause reduction
in blood flow and tumor necrosis [75] and can therefore alter mea-
sures of perfusion (including K trans and IAUGC), vessel permeability
may not be altered. As such, other functional DCE-MRI biomarkers
such as blood plasma volume (vp) within tumor voxels or alternative
biophysical measurements such as enhancing tumor volume could be
measured. Ideally, the biologic end points being sought with DCE-
MRI should relate to the proposed mechanism of action of the drug.
Challenges with Prostate DCE-MRI as a Biomarker
in Clinical Trials
As with quantitative imaging in any cancer clinical trials, there are pitfalls
and challenges that need to be addressed. These include, but are not lim-
ited to, patient and referring physician reluctance and fear of quantitative
Figure 3. To allow for more precise comparison of quantitative changes, posttreatment (post-tx) T2W images were aligned with
pretreatment (pre-tx) T2W images by means of deformable registration. Yellow contour outline shows the capsule of the shrunken
prostate gland in the posttreatment data, which aligns with the capsule in pretreatment in the registered data set.
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imaging components in clinical trials, institutional limitation for quan-
titative imaging, costs involved with including imaging, and concerns
that clinical trials may be underpowered for quantitative imaging [76].
DCE-MRI, however, presents its own unique additional challenges for
its use as a biomarker in clinical trials, addressed below.
DCE-MRI Methodology
DCE-MRI is able to distinguish malignant from benign and normal
tissues by exploiting differences in contrast behavior in their micro-
circulations. Currently, the DCE-MRI protocol is not standardized,
with multiple methodological choices at many levels, making cross-
institutional comparisons challenging. Accurate PK modeling of DCE-
MRI requires knowledge of precontrast native tissue T 1 values [77],
which may be based on literature values [78] or explicitly measured
for each patient. It also requires knowledge of the concentration of the
contrast agent in the feeding vasculature, the so-called arterial input
function (AIF), which can be estimated manually [79,80], through auto-
matic determination of individual AIFs [81–83], or a popular option is
Figure 4.mpMRI demonstrating tumor in the left peripheral zone of the prostate (outlined in blue). Top row: Left: ADC (b= 0, 500), Middle:
T2WI, and Right: subtraction DCE-MRI (early arterial phase − precontrast phase) demonstrate tumor in the left peripheral zone. Bottom
row: Left: K trans map from DCE-MRI also demonstrates tumor in left peripheral zone which is confirmed on (Right) whole-mount (outlined
in red ink) to be Gleason 3 + 4.
Figure 5. Left and middle MR imaging panels: Preprocedural planning mpMRI of the prostate showing anterior area consistent with
suspected tumor cancer presence on the basis of appearance on mpMRI images, particularly subtraction DCE-MRI, K trans map, and
ADCmap (outlined in blue). Right panel: At the time of biopsy, preprocedural T2W diagnostic images are registered to the intraprocedural
T2W image, and targets (arrow) based on diagnostic preprocedure MRI are placed on intraprocedural T2W images. Photograph on
bottom: Transperineal prostate biopsy sample is then obtained, which confirmed a 3 + 4 Gleason grade adenocarcinoma in this case.
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to use a model-based population-averaged AIF, which assumes an a priori
known AIF obtained from population studies [84,85]. Once AIF choice
and prostate T 1 have been decided on, quantitative T 1 changes can be
measured during a high temporal resolution enhancement acquisition
to estimate contrast agent concentration in vivo. The concentration
time curves are mathematically fitted using one of a number of recog-
nized PK models [51] to derive the quantitative parameters. It should
be noted, however, that K trans is vulnerable to model-fitting failures
in cases of motion, in poorly perfused areas, or in highly vascular
areas. IAUGC, conversely, does not require any physiological model,
as it is based on the early part of the gadolinium uptake curve. It is also
difficult to be certain how accurately model-based PK estimates com-
pare with each other and with the physiological parameter that they
supposedly measure, as there is no reliable clinical gold standard.
Nevertheless, quantitative kinetic parameters can provide insights into
underlying pathophysiological processes within the tumor that may
influence drug development.
Optimal Time of Prostate DCE-MRI Measurement
Deciding on the optimal time points for DCE-MRI follow-up is
a challenge, as the exact onset and duration of action of many anti-
angiogenic agents and vascular targeting agents are not well understood.
If imaging is obtained at suboptimal time points, the drug effect win-
dow may be missed. For example, DCE-MRI parameters can change
rapidly (1 day) in glioblastoma multiforme in response to the VEGF
inhibitor cedirinib, and this change can persist for some time (28 days
for glioblastoma multiforme) [7], but this may not be so in other
tumors or with other VEGF inhibitors. In addition, there are limita-
tions to the number and timing of follow-up MRIs that can be ob-
tained for economical, practical, and physiological perspectives. Two
posttherapy MRIs cannot be carried out within 24 hours, until the
effect of gadolinium-induced T 1 relaxation from the first study has
subsided. To minimize patient inconvenience, follow-up MRIs are
usually coincided with follow-up clinical visits. When functional
imaging is to be incorporated into prostate clinical trials, all preclinical
and clinical PK data for that specific drug should help define the
optimal follow-up imaging schedules.
Biomarker Standardization and Validation
Standardization of imaging biomarkers is difficult, as they are
biophysical signals. This is particularly true for DCE-MRI where
PK values obtained may depend on the temporal resolution of the
DCE-MRI study, the reproducibility of the DCE-MRI acquisition
parameters, the measured or assumed T 1 value of the tissue being
measured, the AIF choice, the kinetic model choice, and finally,
whether the data are analyzed on the basis of tumor region of interest
(ROI) or pixel-based data analysis. In addition, it is important to
remember the biophysical dependence of K trans and IAUGC on
blood flow and vessel permeability. The variability and repeatability
of DCE-MRI in the prostate have been evaluated in both in areas of
tumor and normal tissues [86], and the within-subject coefficient of
variation for prostate tumor K trans is reported at 20.1%, similar to
findings in other tumors [87]. Spatial correlation of the pretherapy/
posttherapy changes in the prostate requires additional processing
to align (register) the imaging data collected at the different time
points. To compensate for the changes in the prostate volume, posi-
tion of the patient, and imaging coil, nonrigid registration may be
required (Figure 3).
To support the use of DCE-MRI in PCa clinical trials, it is also
expected that there be a correlation between the biologic effect and
the DCE-MRI PK parameter. Correlation of DCE-MRI parameters
with pathologic measurements is an initial step necessary in PK
parameter validation. mpMRI may be validated using whole-mount
pathologic validation of the prostatectomy specimen after radical
prostatectomy (Figure 4) or by using mpMRI-targeted biopsy of
suspicious prostate lesions (Figure 5).
Awareness of the intrinsic variability of any biomarker on a par-
ticular MR system with a specific protocol is vital for accurate study
pretherapy/posttherapy study design. Standardized protocols and cen-
tralized image analysis may be required for individual clinical studies
if future approval of DCE-MRI as a standard and validated pharma-
codynamic biomarker is to be realized. Uniform quantification across
multiple sites may of course be difficult to achieve, through the use of
different MRI platforms and software packages. Follow-up studies
should obviously be performed using the same equipment and MRI
acquisition methods.
Summary
DCE-MRI in the prostate is a promising biomarker for assessing
response to therapy. Incorporation of functional information from
DCE-MRI into PCa clinical trials will strengthen clinical investiga-
tions. DCE-MRI–derived parameters may provide information about
the action of therapeutics and potentially help in discriminating re-
sponders from nonresponders. Its use, however, requires committed
multidisciplinary teams and very careful quality assurance and stan-
dardization within PCa clinical trials, considering the many potential
variables in arriving at DCE-MRI PK parameters.
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